RNS & Investor News

2022

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2021

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2020

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2019

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2018

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2017

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2016

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2015

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2014

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM

2013

Director and PDMR Dealings

21 April 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it received notification on 20 April 2021 of the following purchases made by Stephen O'Hara (Director and CEO of OptiBiotix Health plc) and René Kamminga (PDMR and CEO of OptiBiotix Limited) on 20 April 2021:

Name

Number of shares purchased

Purchase price

Number of shares held prior to purchase

Resulting shareholding

% of issued share capital

Stephen O'Hara

47,857

53.0p

10,165,129

10,212,986

11.61

René Kamminga

35,000

52.4p

Nil

35,000

0.04

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Stephen O'Hara

b) René Kamminga

2

Reason for notification

 

a.

Position/Status

a) Chief Executive Officer

b) PDMR

b.

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

OptiBiotix Health Plc

b.

LEI

213800UKYQFT941QHS14

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 2p each

ISIN: GB00BP0RTP38

b.

Nature of the transaction

Purchase of ordinary shares in the Company

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

a) 53.0p

b) 52.4p

a) 47,857

b) 35,000

 

 

d.

Aggregated information

-       Volume

-       Price

 

n/a

e.

Date of the transaction

20 April 2021

f.

Place of the transaction

London Stock Exchange, AIM